Paper · 31368038
Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.
Boons G and 4 others. Rev Endocr Metab Disord, 2019. Cited by 13 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. Papers, record 31368038. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31368038
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Intestinal Neoplasms | Major topic |
| Liquid Biopsy | Major topic |
| Neuroendocrine Tumors | Major topic |
| Animals | |
| Humans |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References164
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25,865,046 | A Hereditary Form of Small Intestinal Carcinoid Associated With a Germline Mutation in Inositol Polyphosphate Multikinase. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25865046 | PubMed |
| 2 | 26,058,464 | Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice. | Cancer | 2015 | https://conductscience.org/library/papers/26058464 | PubMed |
| 3 | 26,446,169 | A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. | Cancer Discov | 2015 | https://conductscience.org/library/papers/26446169 | PubMed |
| 4 | 29,467,239 | Frequency and consequence of the recurrent YY1 p.T372R mutation in sporadic insulinomas. | Endocr Relat Cancer | 2018 | https://conductscience.org/library/papers/29467239 | PubMed |
| 5 | 28,903,345 | Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma. | Oncotarget | 2017 | https://conductscience.org/library/papers/28903345 | PubMed |
| 6 | 24,778,027 | Global microRNA profiling of pancreatic neuroendocrine neoplasias. | Anticancer Res | 2014 | https://conductscience.org/library/papers/24778027 | PubMed |
| 7 | 25,947,577 | Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. | Eur J Nucl Med Mol Imaging | 2015 | https://conductscience.org/library/papers/25947577 | PubMed |
| 8 | 23,328,977 | Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. | Mod Pathol | 2013 | https://conductscience.org/library/papers/23328977 | PubMed |
| 9 | 30,667,365 | Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. | Endocr Relat Cancer | 2019 | https://conductscience.org/library/papers/30667365 | PubMed |
| 10 | 27,353,039 | MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. | Endocr Relat Cancer | 2016 | https://conductscience.org/library/papers/27353039 | PubMed |
1 to 10 of 164
See all 164 referencesCited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,278,401 | Prognostic and Predictive Significance of Selected Gene Mutations in Pancreatic and Intestinal Neuroendocrine Tumors. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278401 | PubMed |
| 39,409,968 | The Role of Liquid Biopsy in Gastroenteropancreatic Neuroendocrine Neoplasms. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39409968 | PubMed |
| 36,612,156 | The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36612156 | PubMed |
| 36,556,070 | Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics. | J Clin Med | 2022 | https://conductscience.org/library/papers/36556070 | PubMed |
| 36,085,291 | Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas. | Oncogenesis | 2022 | https://conductscience.org/library/papers/36085291 | PubMed |
| 34,759,042 | Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/34759042 | PubMed |
| 34,733,354 | Primary tumor location (right versus left side of the colon) and resection affect the survival of patients with liver metastases from colonic neuroendocrine carcinoma: a population-based study. | Ther Adv Gastroenterol | 2021 | https://conductscience.org/library/papers/34733354 | PubMed |
| 33,641,005 | Treatment personalization in gastrointestinal neuroendocrine tumors. | Curr Treat Options Oncol | 2021 | https://conductscience.org/library/papers/33641005 | PubMed |
| 32,606,315 | Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. | Sci Rep | 2020 | https://conductscience.org/library/papers/32606315 | PubMed |
| 32,537,434 | Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. | Front Oncol | 2020 | https://conductscience.org/library/papers/32537434 | PubMed |
1 to 10 of 11
See all 11 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATRX | 546 | PubTator's text mining | https://conductscience.org/library/genes/546 | NCBI Gene |
| DAXX | 1,616 | PubTator's text mining | https://conductscience.org/library/genes/1616 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31368038
GET https://conductscience.org/api/papers/v1/31368038/references?page=2